Two‐Year Neurodevelopment and Growth Outcomes for Preterm Neonates Who Received Low‐Dose Intravenous Soybean Oil |
| |
| Authors: | Margaret L. Ong MD Isabell B. Purdy PhD Orly L. Levit MD Daniel T. Robinson MD Tristan Grogan MS Martiniano Flores MS Kara L. Calkins MD MS |
| |
| Affiliation: | 1. David Geffen School of Medicine, University of California, Los Angeles, California, USA;2. Neonatal Research Center of the UCLA Children’s Discovery and Innovation Institute, Division of Neonatology and Developmental Biology, Department of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, California, USA;3. Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut, USA;4. Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA;5. Statistics Core, Department of Medicine, University of California, Los Angeles, California, USA;6. Department of Biostatistics, Fielding School of Public Health, University of California, Los Angeles, California, USA |
| |
| Abstract: | Background: In some studies, the dose of intravenous soybean oil (SO) has been associated with a decreased incidence of intestinal failure–associated liver disease. The effect of lipid sparing on neurodevelopment (ND) and growth remains unknown. This study investigated the impact of SO dose on ND and growth over the first 2 years of age in preterm neonates. Materials and Methods: This is a single‐site prospective follow‐up study. Neonates with a gestational age ≤29 weeks were randomized to low‐dose (LOW) or standard‐dose (CON) SO. Bayley Scales of Infant Development III and anthropometric measurements were collected at approximately 6, 12, and 24 months corrected gestational age. Results: Subjects were premature, with a mean (±SD) gestational age of 28 ± 1 and 27 ± 1 weeks (P = .3) for LOW and CON, respectively. Thirty subjects completed follow‐up (LOW = 15, CON = 15). There were no differences for ND and growth outcomes when LOW was compared with CON, with the exception of a higher 12‐month follow‐up cognitive scaled score in the LOW group (P = .02). Conclusion: A reduced SO dose did not adversely affect ND or growth in this cohort of preterm neonates. However, larger studies are needed to determine the long‐term safety of SO dose reduction before this strategy can be adopted. |
| |
| Keywords: | neonates prematurity lipids fatty acids soybean oil parenteral nutrition growth neurodevelopment |
|
|
